Bladder cancer updates from the first half of 2026

Global oncology innovations: B.J. Kennedy award for geriatric oncology

Global disparities in cancer care for conflict-affected populations: Africa's neglected crisis

ASCO 2026: Updates in bladder cancer

ASCO 2026: Updates in renal cancer

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer

Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy

STRIDE ± lenvatinib plus TACE improves outcomes in unresectable early-to-intermediate HCC

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

ASCO 2026: Lung cancer roundup

ASCO 2026: Comment: Multi-cancer earlier detection tests

Gedatolisib combinations double PFS vs alpelisib in PIK3CA-mutant advanced breast cancer

Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive mTNBC

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

ASCO 2026: Highlights and analysis

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer

Bupropion shows benefit for cancer-related fatigue in cancer survivors

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Short-term fasting linked to improved chemo response in advanced ovarian cancer

FMISO PET-guided radiation dose de-escalation maintains long-term outcomes in HPV-associated oropharyngeal cancer

ASCO 2026: Latest in prostate cancer

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

GLP-1 therapy associated with reduced breast cancer risk

Structured exercise programme improves survival and reduces healthcare costs in colon cancer

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups

Weight loss intervention improves quality of life in breast cancer survivors

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC

GLP-1 use linked to improved survival in patients with cancer

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

Mobile app-based symptom monitoring helps maintain quality of life in advanced cancer

Aspirin use linked to improved survival in endometrial cancer

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours

Implanted tile-based radiation shows promise compared with stereotactic radiotherapy for brain metastases

Daraxonrasib nearly doubles survival in previously treated metastatic pancreatic cancer

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer

Abemaciclib shows benefit in dedifferentiated liposarcoma

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer

Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC

ASCO 2026: Latest updates in mRCC

Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer

Omission of axillary lymph node dissection reduces arm morbidity without compromising survival in select breast cancer cases

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma

ASCO 2026: Breast cancer overview

Bezuclastinib sunitinib combo shows promise in second-line GIST treatment